An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is the most common malignancy and the leading cause of cancer death worldwide. In this report, we describe a patient with NSCLC who was treated with continuation of Bevacizumab (Bev) beyond progression to first-line Bev-based chemotherapy. The prolonged treatment w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Roviello, Giandomenico, Francini, Edoardo, Perrella, Armando, Laera, Letizia, Mazzei, Maria Antonietta, Guerrini, Susanna, Petrioli, Roberto
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Bedside to Bench Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4847824/
https://ncbi.nlm.nih.gov/pubmed/26418066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1095410
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados